Placebo matching BI 1291583

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

29 competitors in Bronchiectasis

#DrugCompanyPhaseTrials

1

Theo-Dur

Pfizer

Approved

22

Cipro

Bayer

Approved

13

Tobrex

VViatris Specialty LLC

Approved

24

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

25

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

16

Merrem

BB. Braun Medical Inc.

Approved

17

Garamycin

SSchering-Plough

Approved

18

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

19

Foradil

Viatris

Approved

—10

Qvar

SSchering-Plough

Approved

—Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Bronchiectasis2 trials

A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)

Recruiting·Boehringer Ingelheim·Phase 3·NCT06872892·1,755 enrolled

A Randomised, Double-blind, Parallel Group, Roll-over Study Evaluating Long-term Safety and Efficacy of Oral Doses of BI 1291583 q.d. in Patients With Bronchiectasis (Clairleafᵀᴹ)

Active, not recruiting·Boehringer Ingelheim·Phase 2·NCT05846230·268 enrolled

Details

Drug Info

Related News